BR9504060A - Composto e formulação farmacêutica - Google Patents

Composto e formulação farmacêutica

Info

Publication number
BR9504060A
BR9504060A BR9504060A BR9504060A BR9504060A BR 9504060 A BR9504060 A BR 9504060A BR 9504060 A BR9504060 A BR 9504060A BR 9504060 A BR9504060 A BR 9504060A BR 9504060 A BR9504060 A BR 9504060A
Authority
BR
Brazil
Prior art keywords
compound
pharmaceutical formulation
formulation
pharmaceutical
Prior art date
Application number
BR9504060A
Other languages
English (en)
Inventor
Labell Elizabeth Smith
Wayne Douglas Luke
John Mcneill Mcgill Iii
Randal Scot Miller
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26976194&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9504060(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/308,325 external-priority patent/US5629425A/en
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR9504060A publication Critical patent/BR9504060A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/56—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
BR9504060A 1994-09-19 1995-09-18 Composto e formulação farmacêutica BR9504060A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/308,325 US5629425A (en) 1994-09-19 1994-09-19 Haloalkyl hemisolvates of 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-piperidinoethoxy)-benzoyl]benzo[b]thiophene
US42791495A 1995-04-26 1995-04-26

Publications (1)

Publication Number Publication Date
BR9504060A true BR9504060A (pt) 1996-09-24

Family

ID=26976194

Family Applications (2)

Application Number Title Priority Date Filing Date
BR9504059A BR9504059A (pt) 1994-09-19 1995-09-18 Processo para a preparação de um solvato cristalino de um composto solvato cristalino processo para a preparação de hidrocloreto de 6-hidróxido-2-(4-hidroxifenil)-3-(4-(2-piperidinoetóxi)benzoil)benzo(B)tiofeno e o hidrocloreto obtido
BR9504060A BR9504060A (pt) 1994-09-19 1995-09-18 Composto e formulação farmacêutica

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR9504059A BR9504059A (pt) 1994-09-19 1995-09-18 Processo para a preparação de um solvato cristalino de um composto solvato cristalino processo para a preparação de hidrocloreto de 6-hidróxido-2-(4-hidroxifenil)-3-(4-(2-piperidinoetóxi)benzoil)benzo(B)tiofeno e o hidrocloreto obtido

Country Status (51)

Country Link
US (4) US6399778B1 (pt)
JP (2) JP2860071B2 (pt)
KR (2) KR100367376B1 (pt)
CN (2) CN1068324C (pt)
AP (1) AP754A (pt)
AT (2) AT407988B (pt)
AU (3) AU692907B2 (pt)
BE (2) BE1009625A3 (pt)
BG (1) BG62793B1 (pt)
BR (2) BR9504059A (pt)
CA (2) CA2158399C (pt)
CH (3) CH691125A5 (pt)
CO (2) CO4410191A1 (pt)
CZ (2) CZ292007B6 (pt)
DE (3) DE19534745B4 (pt)
DK (4) DK175897B1 (pt)
EE (1) EE03386B1 (pt)
EG (1) EG23763A (pt)
ES (2) ES2109882B1 (pt)
FI (2) FI112226B (pt)
FR (2) FR2732020B1 (pt)
GB (2) GB2293382B (pt)
GE (1) GEP19991821B (pt)
GR (2) GR1002697B (pt)
HK (1) HK1019009A1 (pt)
HR (2) HRP950483B1 (pt)
HU (2) HU227683B1 (pt)
IE (2) IE950722A1 (pt)
IL (3) IL115314A (pt)
IS (1) IS1788B (pt)
IT (2) IT1277601B1 (pt)
LU (2) LU88660A1 (pt)
LV (2) LV11178B (pt)
MY (1) MY116371A (pt)
NL (2) NL1001196C2 (pt)
NO (2) NO308107B1 (pt)
NZ (2) NZ280027A (pt)
OA (1) OA10406A (pt)
PE (2) PE14796A1 (pt)
PL (2) PL182450B1 (pt)
PT (2) PT101771B (pt)
RO (2) RO115259B1 (pt)
RS (2) RS49513B (pt)
SE (2) SE509265C2 (pt)
SI (2) SI9500293A (pt)
SK (1) SK283502B6 (pt)
TR (1) TR199501136A2 (pt)
TW (1) TW412534B (pt)
UA (2) UA44240C2 (pt)
UY (1) UY24040A1 (pt)
WO (1) WO1996009045A1 (pt)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE39049E1 (en) 1992-07-28 2006-03-28 Eli Lilly And Company Methods for inhibiting bone loss
USRE38968E1 (en) 1992-07-28 2006-02-07 Eli Lilly And Company Methods for inhibiting bone loss using 6-hydroxy-2-(4-hydroxyphenyl)-benzo[b]thien-3-yl-4-[2-(piperidin-1-yl) ethoxyphenylimethanone hydrochloride
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
US5478847A (en) 1994-03-02 1995-12-26 Eli Lilly And Company Methods of use for inhibiting bone loss and lowering serum cholesterol
CO4410191A1 (es) * 1994-09-19 1997-01-09 Lilly Co Eli SINTESIS DE 3-[4-(2-AMINOETOXI)BENZOIL]-2-ARIL-6- HIDROXIBENZO [b] TIOFENOS
WO1997035571A1 (en) * 1996-03-26 1997-10-02 Eli Lilly And Company Benzothiophenes, formulations containing same, and methods
US6458811B1 (en) * 1996-03-26 2002-10-01 Eli Lilly And Company Benzothiophenes formulations containing same and methods
ZA979720B (en) 1996-10-30 1999-04-29 Lilly Co Eli Prophylaxis of breast cancer
CA2236254A1 (en) * 1997-04-30 1998-10-30 David Warren Hoard Process for preparing benzo¬b|thiophenes
ATE301129T1 (de) 1999-05-04 2005-08-15 Strakan Int Ltd Androgen glykoside und die androgenische aktivität davon
US6921827B2 (en) * 2000-11-27 2005-07-26 Eli Lilly And Company Process for preparing 3-aryl-benzo{b} thiophenes
EP2316469A1 (en) 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
WO2004029046A2 (en) * 2002-09-30 2004-04-08 A/S Gea Farmaceutisk Fabrik Novel raloxifene acid addition salts and/or solvates thereof, improved method for purification of said raloxifene acid addition salts and/or solvates thereof and pharmaceutical compositions comprising these
US6861422B2 (en) 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
US20060106010A1 (en) * 2003-05-27 2006-05-18 Black Larry J Methods for inhibiting bone loss
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004029784A1 (de) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
DE102004030502A1 (de) 2004-06-24 2006-01-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel
DE102004033670A1 (de) 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
US7728134B2 (en) 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US20060035903A1 (en) 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US7759485B2 (en) 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
US20060074088A1 (en) 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
EP1630163A1 (de) 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
SG155996A1 (en) 2004-09-29 2009-10-29 Bayer Schering Pharma Ag Thermodynamically stable form of bay 43-9006 tosylate
US20060068010A1 (en) * 2004-09-30 2006-03-30 Stephen Turner Method for improving the bioavailability of orally delivered therapeutics
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102004058337A1 (de) 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
EA015687B1 (ru) 2006-05-04 2011-10-31 Бёрингер Ингельхайм Интернациональ Гмбх Полиморфы
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
AR062927A1 (es) 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
KR20090082399A (ko) * 2006-10-17 2009-07-30 씨아이피엘에이 엘티디. 벤조티오펜 화합물의 결정형 및 그의 제조방법
US8258291B2 (en) * 2006-10-25 2012-09-04 Mamtek International Limited Process for the preparation of sucralose by the chlorination of sugar with triphosgene (BTC)
US20080103295A1 (en) * 2006-10-25 2008-05-01 David Losan Ho Process for the preparation of sucrose-6-ester by esterification in the presence of solid superacid catalyst
DE102007032451B4 (de) 2007-07-12 2010-09-30 Icfs Gmbh Verfahren zur Herstellung von aromatischen Ketonen
WO2009015004A1 (en) * 2007-07-20 2009-01-29 King Pharmaceuticals Research And Development, Inc. Crystals of (2-amino-4,5,6,7-tetrahydrobenzo[b]thien-3-yl)(4-chlorophenyl)methanone
CA2695406A1 (en) 2007-08-03 2009-02-12 Boehringer Ingelheim International Gmbh Crystalline form of a dihydropteridione derivative
EP2242483B1 (en) * 2007-12-21 2013-02-20 Synthon B.V. Raloxifene composition
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
EP2307399B1 (en) * 2008-06-09 2016-05-18 ERREGIERRE S.p.A. Process for controlling the growth of a raloxifene hydrochloride crystal
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
MX2011002558A (es) 2008-09-10 2011-04-26 Boehringer Ingelheim Int Terapia de combinacion para el tratamiento de diabetes y estados relacionados.
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
CA2745037C (en) 2008-12-23 2020-06-23 Boehringer Ingelheim International Gmbh Salt forms of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8(3-(r)-amino-piperidin-1-yl)-xanthine
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
ES2437916T3 (es) 2009-07-02 2014-01-15 Synthon B.V. Composición de raloxifeno
EP2314581B1 (en) 2009-10-23 2012-07-25 Hexal AG A process for preparing benzo[b]thiophene derivatives
CN107115530A (zh) 2009-11-27 2017-09-01 勃林格殷格翰国际有限公司 基因型糖尿病患者利用dpp‑iv抑制剂例如利拉利汀的治疗
WO2011099942A1 (en) 2010-02-09 2011-08-18 Silverstone Pharma New addition salts of raloxifene, process for the preparation thereof and use thereof in therapy
AU2011249722B2 (en) 2010-05-05 2015-09-17 Boehringer Ingelheim International Gmbh Combination therapy
KR20220025926A (ko) 2010-06-24 2022-03-03 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
IT1403083B1 (it) * 2010-10-25 2013-10-04 Fidia Farmaceutici Nuova forma polimorfa di raloxifene cloridrato
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
KR101985384B1 (ko) 2011-07-15 2019-06-03 베링거 인겔하임 인터내셔날 게엠베하 치환된 퀴나졸린, 이의 제조 및 약제학적 조성물에서의 이의 용도
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP2849755A1 (en) 2012-05-14 2015-03-25 Boehringer Ingelheim International GmbH A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
ZA201401636B (en) 2013-03-05 2014-11-26 Cipla Ltd Oxalic acid addition salts and/or solvates of a selective estrogen receptor modulator
JP2016525532A (ja) 2013-07-26 2016-08-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 骨髄異形成症候群の処置
JP6615109B2 (ja) 2014-02-28 2019-12-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｄｐｐ−４阻害薬の医学的使用
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
CN104496963A (zh) * 2014-12-02 2015-04-08 千辉药业（安徽）有限责任公司 一种盐酸雷洛昔芬的制备方法
CA3022202A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3869485A (en) * 1969-09-25 1975-03-04 Allied Chem Preparation of acid chlorides with phosgene in the presence of a catalyst
GB1456323A (en) * 1974-06-06 1976-11-24 Labaz Benzothiophenes process for preparing them and pharmaceutical compositions containing the same
US4133814A (en) 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
ZA822247B (en) 1981-04-03 1983-11-30 Lilly Co Eli Benzothiophene compounds and process for preparing them
EP0062503A1 (en) * 1981-04-03 1982-10-13 Eli Lilly And Company Benzothiophene compounds and process for preparing them
IL65378A (en) * 1981-04-03 1986-02-28 Lilly Co Eli Process for preparing 3-(4-aminoethoxybenzoyl)benzo-(b)thiophenes
US4418068A (en) 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
IL65379A0 (en) 1981-04-03 1982-05-31 Lilly Co Eli Process for preparing acylated benzothiophenes
US4380635A (en) 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US4358593A (en) * 1981-04-03 1982-11-09 Eli Lilly And Company Process for preparing 3-(4-aminoethoxybenzoyl)benzo[b]thiophenes
DE4117512A1 (de) * 1991-05-25 1992-11-26 Schering Ag 2-phenylbenzo(b)furane und -thiophene, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体
US5169860A (en) * 1992-03-13 1992-12-08 Eli Lilly And Company Antitumor compositions and methods of treatment
TW383306B (en) 1992-12-22 2000-03-01 Lilly Co Eli New use of 2-phenyl-3-aroylbenzothiophenes in lowering serum cholesterol
DE69405491T2 (de) 1993-06-24 1998-02-19 Lilly Co Eli Antiöstrogene 2-Phenyl-3-Aroylbenzothiophene als hypoglykämische Mittel
US6756388B1 (en) * 1993-10-12 2004-06-29 Pfizer Inc. Benzothiophenes and related compounds as estrogen agonists
US5523416A (en) 1994-07-22 1996-06-04 Eli Lilly And Company Process for preparing 3-(4-aminoethoxy-benzoyl) benzo (B)-thiophenes
CO4410191A1 (es) * 1994-09-19 1997-01-09 Lilly Co Eli SINTESIS DE 3-[4-(2-AMINOETOXI)BENZOIL]-2-ARIL-6- HIDROXIBENZO [b] TIOFENOS

Also Published As

Publication number Publication date
ES2109882B1 (es) 1998-08-16
SI9500293A (en) 1996-06-30
BG101242A (en) 1998-03-31
AU692907B2 (en) 1998-06-18
DK175903B1 (da) 2005-06-06
SE520721C2 (sv) 2003-08-12
US6472531B1 (en) 2002-10-29
NO953657L (no) 1996-03-20
HRP950482A2 (en) 1998-02-28
IT1277602B1 (it) 1997-11-11
CA2158399A1 (en) 1996-03-20
NL1001196A1 (nl) 1996-03-19
SI9500292A (en) 1996-06-30
ITMI951935A1 (it) 1997-03-15
NO953658L (no) 1996-03-20
NO953657D0 (no) 1995-09-15
JP2860071B2 (ja) 1999-02-24
DK175897B1 (da) 2005-05-30
HRP950483A2 (en) 1997-10-31
CH691478A5 (de) 2001-07-31
AU3173095A (en) 1996-04-04
LU88661A1 (fr) 1996-07-15
FR2732020B1 (fr) 1997-11-14
ITMI951936A1 (it) 1997-03-15
KR100381346B1 (ko) 2004-04-13
TR199501136A2 (tr) 1996-06-21
US5731327A (en) 1998-03-24
ES2129293A1 (es) 1999-06-01
AT407988B (de) 2001-07-25
IL125283A (en) 2001-06-14
UA42716C2 (uk) 2001-11-15
US20020173645A1 (en) 2002-11-21
FI954403A (fi) 1996-03-20
NO308107B1 (no) 2000-07-24
SE509265C2 (sv) 1998-12-21
NO313996B1 (no) 2003-01-13
KR960010634A (ko) 1996-04-20
AU691955B2 (en) 1998-05-28
IE80883B1 (en) 1999-05-19
FR2724655A1 (fr) 1996-03-22
OA10406A (en) 2001-12-05
ATA154295A (de) 2000-12-15
GB2293382A (en) 1996-03-27
FI112226B (fi) 2003-11-14
FI121424B (fi) 2010-11-15
IT1277601B1 (it) 1997-11-11
FR2724655B1 (fr) 1997-11-14
CH691594A5 (de) 2001-08-31
PE32796A1 (es) 1996-08-07
CN1075069C (zh) 2001-11-21
MY116371A (en) 2004-01-31
IS4446A (is) 1997-03-18
GB9519032D0 (en) 1995-11-15
UA44240C2 (uk) 2002-02-15
FI954402A0 (fi) 1995-09-18
US6399778B1 (en) 2002-06-04
KR100367376B1 (ko) 2003-03-06
GB9519028D0 (en) 1995-11-15
SE9503214D0 (sv) 1995-09-15
DE19534744A1 (de) 1996-03-21
HU225417B1 (en) 2006-11-28
HUT74178A (en) 1996-11-28
SE9503213L (sv) 1996-03-20
EE03386B1 (et) 2001-04-16
DK175887B1 (da) 2005-05-23
IL115314A0 (en) 1996-05-14
CO4410191A1 (es) 1997-01-09
HUT75033A (en) 1997-03-28
BE1009625A3 (fr) 1997-06-03
AU3173195A (en) 1996-04-04
RS49513B (sr) 2006-10-27
NL1001196C2 (nl) 1997-04-04
NZ280027A (en) 1997-05-26
PL310518A1 (en) 1996-04-01
SE9503213D0 (sv) 1995-09-15
EG23763A (en) 2007-08-08
IS1788B (is) 2001-11-28
JPH08193081A (ja) 1996-07-30
IE950722A1 (en) 1996-03-20
GB2293382B (en) 1998-08-19
YU61495A (sh) 1998-05-15
PT101771A (pt) 1996-04-30
ITMI951935A0 (it) 1995-09-15
CA2158400A1 (en) 1996-03-20
AT502957A1 (de) 2007-06-15
NZ280028A (en) 1997-05-26
CZ292007B6 (cs) 2003-07-16
ES2129293B1 (es) 2000-01-16
NO953658D0 (no) 1995-09-15
ITMI951936A0 (it) 1995-09-15
PL182450B1 (pl) 2002-01-31
BE1009626A3 (fr) 1997-06-03
UY24040A1 (es) 1996-03-07
DE19549755B4 (de) 2005-05-04
CN1068324C (zh) 2001-07-11
SE9503214L (sv) 1996-03-20
IL115315A0 (en) 1995-12-31
GB2293602B (en) 1998-05-06
LV11177A (lv) 1996-04-20
SK283502B6 (sk) 2003-08-05
AU3718695A (en) 1996-04-09
CA2158399C (en) 2001-03-20
LU88660A1 (fr) 1996-07-15
FR2732020A1 (fr) 1996-09-27
FI954402A (fi) 1996-03-20
NL1001194C2 (nl) 1997-04-04
HU227683B1 (en) 2011-11-28
GR1002709B (el) 1997-06-04
AP9700938A0 (en) 1997-04-30
CH691125A5 (de) 2001-04-30
BG62793B1 (bg) 2000-08-31
HRP950483B1 (en) 2003-02-28
CZ240295A3 (en) 1996-04-17
WO1996009045A1 (en) 1996-03-28
RO115260B1 (ro) 1999-12-30
IL115314A (en) 2000-02-29
GB2293602A (en) 1996-04-03
HRP950482B1 (en) 2007-04-30
KR960010637A (ko) 1996-04-20
DK102795A (da) 1996-03-20
DK102895A (da) 1996-03-20
FI954403A0 (fi) 1995-09-18
NL1001194A1 (nl) 1996-03-19
PT101770B (pt) 1997-04-30
IL115315A (en) 1999-09-22
CO4410190A1 (es) 1997-01-09
ES2109882A1 (es) 1998-01-16
IE950721A1 (en) 1996-03-20
HK1019009A1 (en) 2000-01-14
CN1127253A (zh) 1996-07-24
DE19534745A1 (de) 1996-04-04
CA2158400C (en) 2006-10-24
DE19534745B4 (de) 2004-06-09
DK2897A (da) 1997-01-09
CZ240395A3 (en) 1996-04-17
DK175886B1 (da) 2005-05-23
AP754A (en) 1999-07-22
PL187686B1 (pl) 2004-09-30
PE14796A1 (es) 1996-05-19
BR9504059A (pt) 1996-09-24
CZ290343B6 (cs) 2002-07-17
EE9700055A (et) 1997-08-15
RO115259B1 (ro) 1999-12-30
JPH08176147A (ja) 1996-07-09
LV11178A (lv) 1996-04-20
TW412534B (en) 2000-11-21
LV11177B (en) 1996-08-20
DK2797A (da) 1997-01-09
HU9502723D0 (en) 1995-11-28
YU61395A (sh) 1998-09-18
GEP19991821B (en) 1999-11-05
PT101770A (pt) 1996-04-30
CN1132205A (zh) 1996-10-02
LV11178B (en) 1996-08-20
GR1002697B (el) 1997-05-22
SK23397A3 (en) 1997-08-06
RS49578B (sr) 2007-04-10
PT101771B (pt) 1997-04-30
PL310517A1 (en) 1996-04-01
HU9502721D0 (en) 1995-11-28

Similar Documents

Publication Publication Date Title
BR9500784A (pt) Composto e formulação farmacêutica
BR9504060A (pt) Composto e formulação farmacêutica
BR1100329A (pt) Composto e formulação farmacêutica
DE69525148D1 (de) Pharmazeutische formulierung
NO954486D0 (no) Farmasöytiske formuleringsgrunnlag
BR1100824A (pt) Composto e composição farmacêutica
ID24654A (id) Formulasi farmasi omeprazola
DE69513671D1 (de) Arzneimittel
KR950703566A (ko) 티에노디아제핀 화합물 및 그의 의약 용도[thienodiazepine compound and medicinal use thereof]
NO981008D0 (no) Farmasöytisk formulering
BR9607851B1 (pt) combinaÇço e formulaÇço farmacÊutica.
BR9200058A (pt) Composto e composicao farmaceutica
BR9707812A (pt) Composto composto farmacêutica e uso do composto
DE69524592T2 (de) 2-Acylaminopropanolverbindung und ihre pharmazeutische Zusammensetzung
ATA181095A (de) Probiotisch wirksame formulierung
BR9509688A (pt) Composto e composição farmacêutica
BR9507768A (pt) Composição farmacêutica
ITMI941169A0 (it) Formulazioni farmaceutiche
ITMI942166A0 (it) Composizioni farmaceutiche miorilassanti
FI973230A0 (fi) Uusi farmaseuttinen formulaatio
FI951155A0 (fi) Farmaseuttinen valmiste
BR9606066A (pt) Composto e formulação farmacêutica
FI962738A (fi) Farmaseuttiset koostumukset
BR9507059A (pt) Formulação veterinária
BR9505130A (pt) Composto e composiçao farmacêutica

Legal Events

Date Code Title Description
FF Decision: intention to grant
HIFF Patent grant cancelled
HJEG Technical examination (opinion): technical examination (opinion) related to article 229 of industrial property law
FF Decision: intention to grant
FG9A Patent or certificate of addition granted
B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 18/09/2015